Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis

Study Overview
=================
Brief Summary
-----------------
The clinical study investigates the long-term course of disease in patients with chronic inflammatory skin diseases (atopic eczema and psoriasis) and the impact of tarheted therapies on the clinical and molecular level. For this purpose, patients are asked to take part in regular examinations and data collections, and to donate biomaterials (blood, skin biopsies, skin swabs, tape strips, stool samples). Blood samples are used to analyze inflammation messengers. Punch biopsies from lesional and non-lesional skin areas are used to analyze gene expression. Tape strips are pieces of transparent adhesive tapes to strip off most of the horny layer that will be used to examine mRNA and protein expression. The skin smears are superficial smears of three areas of skin with cotton swabs, which are used to examine bacteria on the skin. Overall, the study will help to monitor the disease course clinically and on the molecular level in participating patients for at least ten years and to collect information about the impact of various external factors including treatments. The study has no effect on the therapies of the disease, it serves only the accompanying data collection

Detailed Description
-----------------
Atopic dermatitis and psoriasis are the most common chronic inflammatory skin diseases in dermatology. Due to genetic predispositions, inflammatory changes of the skin occur. The specific mechanisms are only partly understood for both diseases and targeted therapies are established in psoriasis therapy and are becoming available for atopic dermatitis. In order to better understand the course of the disease and to characterize the changes in the inflammatory mechanisms during the course of the disease and under the influence of external factors such as therapies, longitudinal prospective studies are needed to evaluate clinical data and biological samples. This study investigates long-term clinical and epidemiological data from affected patients, as well as biological samples, including blood samples, skin biopsies, non-invasive skin swabs for microbiome detection, and tape strips for the molecular characterization of the disease. Data collection and biosampling will be done during routine visits, typically at week 0, 2, 12 and 52.

Official Title
-----------------
Disease Trajectories in Atopic Dermatitis and Psoriasis

Conditions
-----------------
Atopic Dermatitis, Psoriasis, Healthy

Intervention / Treatment
-----------------
* Other: Biosampling for molecular analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a clinical diagnosis of atopic dermatitis, psoriasis or autoimmune skin disease Written informed consent obtained from the subject Exclusion Criteria: Patients who decline participation In patients<18 years of age no biopsies will be taken

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atopic dermatitis<br>Patients with dermatologist-diagnosed atopic dermatitis, psoriasis or autoimmune skin disease. | Other: Biosampling for molecular analysis<br>* Observational study with no therapeutic intervention. Biosampling for molecular analysis<br>|
| Controls<br>Healthy volunteers with no history of atopic, autoimmune or chronic inflammatory disease. | Other: Biosampling for molecular analysis<br>* Observational study with no therapeutic intervention. Biosampling for molecular analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease progression | Epidemiological and phenotypical data of patients | 10 years | 
| Molecular signature changes | Molecular signatures will be measured using OMICS and sequencing technologies | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of comorbidities | Assessment of newly developed comorbid diseases over time | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Disease progression, Disease course, Immunological characterization